FDA grants orphan-drug status to Erytech's leukemia drug

01/27/2010 | American City Business Journals

Graspa, Erytech Pharma's drug candidate for acute lymphoblastic leukemia, received orphan-drug designation from the FDA. The drug is a novel L-asparaginase formulation packed in red blood cells to make it safer. Erytech is considering starting clinical trials of the drug in the U.S., CEO Yann Godfrin said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC